Yen Vo-Hoang

Dr. Yen Vo-Hoang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
OBOlivier Berger
Olivier Berger
SOStéphanie Ortial
Stéphanie Ortial
SWSharon Wein
Sharon Wein
SDSéverine Denoyelle
Séverine Denoyelle
FBFrançoise Bressolle
Françoise Bressolle
YVYen Vo-Hoang
Yen Vo-Hoang

24 January 2020 in Cells
Verified
Journal Article
Open access
PDF file
YVYen Vo-Hoang
Yen Vo-Hoang
SPSergio Paiva
Sergio Paiva
LHLeilei He
Leilei He
SESébastien Estaran
Sébastien Estaran
Yong TengYong Teng
Yong Teng
Background: Head and neck squamous cell carcinoma (HNSCC) is one of the leading causes of cancer-related deaths and calls for new druggable targets. We have previously highlighted the critical role of ADP-ribosylation factor-1 (Arf1) activation in HNSCC. In the present study, we address the question whether targeting Arf1 could be proposed as a valuable strategy against HNSCC. Methods: We rationally designed and synthesized constrained ATC-based (4-amino-(methyl)-1,3-thiazole-5-carboxylic acid) γ-dipeptides to block Arf1 activation. We evaluated the effects of these γ-dipeptides in HNSCC cells: The cell viability was determined in 2D and 3D cell cultures after 72 h treatment and Arf1 protein levels and activity were assessed by GGA3 pull-down and Western blotting assays. Results: Targeting Arf1 offers a valuable strategy to counter HNSCC. Our new Arf1-targeting compounds revealed a strong in vitro cytotoxicity against HNSCC cells, through inhibiting Arf1 activation and its downstream pathways. Conclusions: Arf1-targeting γ-dipeptides developed in this study may represent a promising targeted therapeutic to improve managing the HNSCC disease.

1 June 2023 in Journal of Integrative Bioinformatics
Verified
Journal Article
Open access
PDF file
TPThomas Papastergiou
Thomas Papastergiou
JAJérôme Azé
Jérôme Azé
SBSandra Bringay
Sandra Bringay
MLMaxime Louet
Maxime Louet
PPPascal Poncelet
Pascal Poncelet
LGLaurent Gavara
Laurent Gavara
NDM-1 (New-Delhi-Metallo-β-lactamase-1) is an enzyme developed by bacteria that is implicated in bacteria resistance to almost all known antibiotics. In this study, we deliver a new, curated NDM-1 bioactivities database, along with a set of unifying rules for managing different activity properties and inconsistencies. We define the activity classification problem in terms of Multiple Instance Learning, employing embeddings corresponding to molecular substructures and present an ensemble ranking and classification framework, relaying on a k-fold Cross Validation method employing a per fold hyper-parameter optimization procedure, showing promising generalization ability. The MIL paradigm displayed an improvement up to 45.7 %, in terms of Balanced Accuracy, in comparison to the classical Machine Learning paradigm. Moreover, we investigate different compact molecular representations, based on atomic or bi-atomic substructures. Finally, we scanned the Drugbank for strongly active compounds and we present the top-15 ranked compounds.